Symptomatic treatment of myasthenia gravis, and in particular ptosis, is based on acetylcholinesterase inhibitors such as pyridostigmine. American clinicians have reported the beneficial effect of an ophthalmic eye drop administered daily to two patients suffering from a purely ocular form of myasthenia.
- The eye drops contained oxymetazoline hydrochloride.
- This compound is an alpha sympathomimetic usually used as a nasal decongestant due to its vaso-constrictive properties,
- The effect was very positive, lasting for several months and comparable to that already noted in the treatment of ptosis linked to blepharospasm, for which the product has been approved by the FDA.